14 results
SC 14D9
THRX
Theseus Pharmaceuticals Inc
10 Jan 24
Tender offer solicitation
9:47am
workforce reduction following the Theseus Board’s determination in November 2023 that continued independence would not maximize value for the Company’s
8-K
THRX
Theseus Pharmaceuticals Inc
4 Dec 23
Departure of Directors or Certain Officers
6:30am
of Certain Officers.
Termination of Timothy P. Clackson, Ph.D.
As part of a reduction in workforce, Theseus Pharmaceuticals, Inc. (the “Company … , M.D.
As part of the reduction in workforce, the Company also terminated the employment of David Kerstein, M.D. as the Chief Medical Officer
8-K
EX-99.1
THRX
Theseus Pharmaceuticals Inc
13 Nov 23
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
4:06pm
a process exploring strategic alternatives to maximize shareholder value.
In conjunction with the strategic process, Theseus implemented a workforce
8-K
THRX
Theseus Pharmaceuticals Inc
13 Nov 23
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
4:06pm
a workforce reduction of the Company’s workforce by 26 full-time employees, or approximately 72% of the Company’s then-current employee base … against the Company. The reduction of workforce is expected to result in $5.5 million in severance costs. The incremental costs are expected
10-K
fbrg867cv3
10 Mar 22
Annual report
7:23am
10-Q
1yfpkjp
15 Nov 21
Quarterly report
7:36am
424B4
nw0 8gq8b899hi
7 Oct 21
Prospectus supplement with pricing info
5:03pm
S-1/A
EX-10.15
w882uffejf21gzn3h
30 Sep 21
IPO registration (amended)
6:33am
S-1/A
khi1mqmq5wm3 813hgr
30 Sep 21
IPO registration (amended)
6:33am
S-1
2hl3a o6j60o9f8f
15 Sep 21
IPO registration
4:04pm
DRS/A
q8wn1v 4g
23 Aug 21
Draft registration statement (amended)
12:00am
DRS
8wnh9d
20 Jul 21
Draft registration statement
12:00am
- Prev
- 1
- Next